You are viewing the site in preview mode
Skip to main content
| |
Clinical success at day 14 (N = 152)
|
Clinical failure at day 14 (N = 549)
|
P value
|
|---|
|
Age (Mean ± SD), year
|
62.79 (18.514)
|
66.08 (16.975)
|
0.038
|
|
Gender (female)
|
68 (44.7%)
|
184 (33.5%)
|
0.011
|
|
Country
| | |
0.001
|
|
Israel
|
113 (74.3%)
|
431 (78.5%)
| |
|
Greece
|
32 (21.1%)
|
60 (10.9%)
| |
|
Italy
|
7 (4.6%)
|
58 (10.6%)
| |
|
Hematological malignancy
|
2 (1.3%)
|
37 (6.7%)
|
0.010
|
|
Congenative heart failure
|
25 (16.4%)
|
133 (24.2%)
|
0.042
|
|
Arterial line
|
35 (23%)
|
192 (35%)
|
0.005
|
|
Chronic pulmonary disease
|
23 (15.1%)
|
125 (22.8%)
|
0.041
|
|
Systolic blood pressure, mm Hg (SD)
|
111.97 (20.539)
|
106.66 (22.499)
|
0.009
|
|
Haemodynamic support
|
16 (10.6%)
|
127 (23.7%)
|
0.000
|
|
Mechanical ventilation (invasive)
|
81 (53.6%)
|
381 (70.6%)
|
0.000
|
|
Haemodialysis
|
1 (0.7%)
|
37 (6.9%)
|
0.003
|
|
Creatinine clearance (Cockcroft-Gault Equation), mL/min (Percentiles 25–75)
|
72.60 (41.16–132.14)
|
64.01 (36.08–118.69)
|
0.199
|
|
Albumin, g/dL (SD)
|
2.46 (0.678)
|
2.327 (0.6383)
|
0.035
|
|
Nasogastric tube
|
92 (60.5%)
|
394 (71.8%)
|
0.008
|
|
Pathogen
|
|
Acinetobacter baumannii
|
100 (65.8%)
|
448 (81.6%)
|
0.000
|
|
Enterobacteriacaeae
|
35 (23%)
|
73 (13.3%)
|
0.003
|
|
Pseudomonas/other
|
17 (11.1%)
|
28 (5.1%)
|
0.007
|
|
Type of infection
|
|
Bacteraemia
|
68 (44.7%)
|
214 (39%)
|
0.200
|
|
Ventilator-associated or hospital-acquired pneumonia
|
55 (36.2%)
|
267 (48.6%)
|
0.006
|
|
Probable ventilator-associated pneumonia
|
10 (6.6%)
|
29 (5.3%)
|
0.537
|
|
Urinary tract infection
|
19 (12.5%)
|
39 (7.1%)
|
0.033
|
|
Acquisition of infection in the intensive care unit
|
24 (15.6%)
|
167 (30.4%)
|
0.000
|
|
Exclusion from the RCT
|
53 (34.9%)
|
242 (44.1%)
|
0.042
|
|
Colistin MIC distribution > 0.5 mg/L
|
27 (21.3%), n = 127
|
76 (16.7%), n = 456
|
0.230
|
|
Antibiotic treatment
|
|
Combination arm: colistin and meropenem
|
68 (50.7%), n = 134
|
193 (44.1%), n = 438
|
0.174
|
|
No loading dose
|
12 (9.0%), n = 134
|
62 (14.2%), n = 438
|
0.117
|
|
Treatment days in patients alive ≥14 days, median (Percentiles 25–75)
|
13 (8–16)
|
8 (4–14)
|
0.000
|
|
Mean colistin maintenance dose per day, million units (Percentiles 25–75)
|
7.9 (5.0–9.0)
|
7.2 (4.0–9.0)
|
0.330
|
- aNumbers apply to all patients in the group unless stated otherwise
